It’s an increasingly familiar scenario. A worker at a cutting-edge tech company in Silicon Valley relocates to China and starts a competing company, and accusations of stolen trade secrets start flying.
But there’s a twist in Friday’s suit from biocatalyst developer Codexis Inc. against EnzymeWorks Inc. EnzymeWorks CEO Junhua “Alex” Tao isn’t a former employee, but allegedly gained access to confidential biomaterials as part of a research partnership between Codexis and a larger pharmaceutical company.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
